Harald Petry
Geen lopende functies
Profiel
Harald Petry worked as Director of Research & Development at Amsterdam Molecular Therapeutics (AMT) Holding NV from 2007 to 2013.
He also worked as Principal at Jenapharm GmbH & Co. KG and Berlex Biosciences.
From 2012 to 2017, he served as Chief Scientific Officer at uniQure NV.
Petry holds a doctorate degree from the University of Giessen.
Eerdere bekende functies van Harald Petry
| Bedrijven | Functie | Einde |
|---|---|---|
| UNIQURE N.V. | Hoofd Techniek/Wetenschap/O&O | 07-08-2017 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Hoofd Techniek/Wetenschap/O&O | 11-03-2013 |
| Berlex Biosciences | Corporate Officer/Principal | - |
Jenapharm GmbH & Co. KG
 Jenapharm GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Jenapharm GmbH & Co. KG manufactures and distributes pharmaceutical products. It offers cures for erectile dysfunction, testosterone deficit, and hyperactivity. It also provides contraceptives, menopause pills, and food supplements. The company was founded in 1950 and is headquartered in Jena, Germany. | Corporate Officer/Principal | - |
Opleiding van Harald Petry
| University of Giessen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| UNIQURE N.V. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Jenapharm GmbH & Co. KG
Jenapharm GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Jenapharm GmbH & Co. KG manufactures and distributes pharmaceutical products. It offers cures for erectile dysfunction, testosterone deficit, and hyperactivity. It also provides contraceptives, menopause pills, and food supplements. The company was founded in 1950 and is headquartered in Jena, Germany. | Health Technology |
| Berlex Biosciences |
